An Update on COVID-19 from GREENSTONE LLC
May 5, 2020

Dear Valued Customer,

As a result of the COVID-19 pandemic, GREENSTONE LLC has taken proactive steps to protect the health and safety of our colleagues and maintain supply of our medicines to ensure that patients receive the medicines they need.

At this time, we have asked colleagues who are able to perform their job functions outside of a Pfizer facility to work remotely.  We are adjusting to the “new normal” and maintaining a high level of productivity. Certain colleagues, such as those in manufacturing and supply chain, have roles whose physical presence is required to perform their job function. These colleagues continue to report to work, but are subject to strict protocols intended to reduce the risk of transmission. These measures are important for the health and well-being of our colleagues, our patients, our customers, and our community.

As noted in Pfizer’s quarterly earnings release dated April 28, 2020, the company has implemented its preparedness plan to control site operations. To date, Greenstone has not seen a significant disruption in its supply chain, and all of the related manufacturing sites around the world have continued to operate at or near normal levels. Consistent with our communication on March 23rd, we do not anticipate any COVID-19 related shortages of product in the United States.

We know these are challenging times and are grateful to you for your support of patients and our relationship. As the situation improves, we will be ready to re-engage and re-connect together beyond our virtual environment today.

If you have questions, please contact your Account Director or customer service at 1-800-447-3360.